Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

NCT02525679 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BI 655130 (spesolimab)
DRUG: Placebo

Sponsor

Boehringer Ingelheim